Companies /Healthcare
CVS Health Corp
NYSE: CVS Healthcare Plans
$80.84
▲ $0.80 (+1.00%) today
Markets closed · 1:40pm ET

CVS Health (CVS) Q3 2026 Earnings

Reported Nov 4, 2026, 6:30am ET
$2.09
Beat +26.61%
EPS · est. $1.65 Adjusted

Adjusted EPS excludes $425 million amortization of intangible assets, a $193 million Omnicare guarantee charge, $13 million acquisition-related integration costs and $(3) million net realized capital gains, net of $(103) million tax impact. GAAP diluted EPS was $1.68.

$108.4B
Beat +3.54%
Revenue · est. $104.7B
7 quarters
Consecutive EPS beats

How Did CVS Stock React to Q3 2026 Earnings?

% change · around the report
−15%−10%−5%0Nov 4Nov 5report 6:30am ETearnings−3.1%−12.7%
−15%−10%−5%0Nov 4Nov 5earnings−3.1%−12.7%
CVS −12.7%S&P 500 −3.1%
−15%−10%−5%0Nov 4Nov 5report 6:30am ETearnings−5.3%−12.7%
−15%−10%−5%0Nov 4Nov 5earnings−5.3%−12.7%
CVS −12.7%NASDAQ −5.3%
−12%−8%−4%0Nov 3Nov 12report 6:30am ETearnings−0.9%+0.4%
−12%−8%−4%0Nov 3Nov 12earnings−0.9%+0.4%
CVS +0.4%S&P 500 −0.9%
−12%−8%−4%0Nov 3Nov 12report 6:30am ETearnings−1.3%+0.4%
−12%−8%−4%0Nov 3Nov 12earnings−1.3%+0.4%
CVS +0.4%NASDAQ −1.3%
−12.53%
Day of report
+1.71%
Next session
+11.96%
One week

Did CVS Beat Earnings? Q3 2026 Results

Yes. CVS Health reported Q3 2026 earnings of $2.09 a share on Nov 4, 2026, beating the $1.65 consensus estimate by 26.6%. Revenue was $108.4B against a $104.7B estimate.

CVS Health delivered a standout third quarter of 2026, posting adjusted EPS of $2.09 against a consensus estimate of $1.65, a beat of 26.61% that extended the company's streak of topping Wall Street's EPS forecasts to six consecutive quarters. Revenue climbed 5.4% year over year to $108.40 billion, clearing the $104.69 billion consensus by 3.54%, as all three operating segments contributed to consolidated adjusted operating income growth of 21.2% to $4.19 billion. The single largest driver was a sharp recovery in the Health Care Benefits segment, where Aetna's medical benefit ratio improved to 91.3% from 92.8% and adjusted operating income surged to $912 million from $314 million a year ago. GAAP diluted EPS came in at $1.68, a dramatic improvement from the prior-year period that was burdened by a multi-billion-dollar goodwill impairment. Looking ahead, management raised full-year 2026 adjusted EPS guidance to at least $8.20, up from a prior range of $7.90 to $8.10, and lifted its operating cash flow target to at least $15.50 billion, even as reports of a potential corporate breakup into two publicly traded companies added a broader strategic dimension to the quarter's results.

Key Takeaways
  • Health Care Benefits adjusted operating income rose to $912 million from $314 million on improved underlying Government business performance
  • Health Care Benefits MBR improved to 91.3% from 92.8%
  • Government premiums up 8.2% to $28.1 billion
  • Health Services revenue up 9.5% on pharmacy drug mix and brand inflation
  • Health Services adjusted operating income up 2.7% on improved purchasing economics and drug mix
  • Pharmacy & Consumer Wellness adjusted operating income up 10.6% on core pharmacy strength and Rite Aid asset acquisitions
  • Prescriptions filled up 1.9% and pharmacy claims processed up 1.3% on a 30-day equivalent basis
  • Prior years' health care cost estimates developed favorably by $1.3 billion year-to-date
  • Absence of the prior-year $5.7 billion goodwill impairment drove the GAAP swing to profit

“Our colleagues build trust every day through delivering quality health care rooted in our purpose - to simplify health care one person, one family and one community at a time. Through their continued dedication, each of our businesses delivered another quarter of strong results.”

CVS Health CEO, on the earnings call

What Is CVS Health's Outlook?

CVS raised its full-year 2026 guidance: - Total revenues of at least $420.0 billion. - GAAP diluted EPS of at least $6.98, versus a prior range of $6.84 to $7.04. - Adjusted EPS of at least $8.20, versus $7.90 to $8.10. - Cash flow from operations of at least $15.5 billion, versus at least $11.5 billion. The guidance reconciliation projects: - Net income attributable to CVS Health of at least $9,002 million. - Adjusted income of at least $10,571 million. - Weighted average diluted shares of 1,289 million. - Excluded items of $1,730 million in intangible amortization, $26 million in net realized capital losses, $80 million in integration costs and the $193 million Omnicare guarantee, net of a $(460) million tax impact. The increases reflect stronger Health Care Benefits and Pharmacy & Consumer Wellness performance. Management is maintaining a cautious view for the rest of the year given continued elevated cost trends and potential macro headwinds.

CVS YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$30.0B$60.0B$90.0B$102.9B$108.4BRevenue$1.1B$3.6BOperating Income$853.0M$2.2BNet Income
$0$30.0B$60.0B$90.0BRevenueOperating IncomeNet Income
CVS income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $108.4B $102.9B +5.4%
Operating Income $3.6B $1.1B +211.2%
Net Income $2.2B $853.0M +154.6%

CVS Revenue by Segment

Health Services$54.0B+9.5%
Pharmacy & Consumer Wellness$35.5B−2.0%
Health Care Benefits$36.9B+2.4%
Pharmacy$29.7B−2.3%
Government Premiums$28.1B+8.2%
Pharmacy Network
Mail & Specialty
Commercial Premiums$6.5B−16.9%

When Does CVS Health Report Next?

Expected report date
After the close
Release timing

Figures from SEC filings and company reports. Not investment advice.